AveXis Competitors, Revenue, Alternatives and Pricing

Claim your profile


Chicago, IL USA
Total Funding:$170.5M
Lead Investor(s):Goldman Sachs & Co. LLC, Jefferies LLC

Industry Ranking

Estimated Revenue & Financials

  • AveXis's estimated annual revenue is currently $211.3M per year.
  • AveXis received $460.0M in venture funding in January 2018.
  • AveXis's estimated revenue per employee is $155,000
  • AveXis's total funding is $170.5M.

Employee Data

  • AveXis has 1363 Employees.
  • AveXis grew their employee count by 147% last year.
  • AveXis currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Project Farma
Heidolph North ...
Orochem Technol...
Horizon Therape...
Project Farma
Missing a competitor? Contribute!?

AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. How to reach us: AveXis, Inc. 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: info@avexis.com Office Phone: 847.572.8280 Toll-free Phone: 844.4.AVEXIS (844.428.3947)



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







AveXis News

09/03/2019 - Warning signs were always there for Novartis's Avexis deal

High-profile departures at Avexis raise more questions about Novartis's acquisition, but there were plenty of red flags before the deal was ...

08/20/2019 - Ousted AveXis CSO denies wrongdoing in Novartis data ...

In a statement, former AveXis chief scientific officer Brian Kaspar said he "categorically denies any wrongdoing" in the Zolgensma data scandal.

09/03/2019 - Global Spinal Muscular Atrophy Medicine Market 2019 ...

The global market for Spinal Muscular Atrophy Medicine has been analyzed in an in-depth market research report recently added to the rapidly ...

AveXis Funding

DateAmountRoundLead InvestorsReference
2014-04-24$UndisclosedUndisclosedPBM Capital GroupArticle
2015-01-08$10.0MUndisclosedDeerfield ManagementArticle
2015-09-10$65.0MDT. Rowe Price AssociatesArticle
2017-06-21$230.0MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-17$460.0MUndisclosedGoldman Sachs & Co. LLCArticle

AveXis Executive Hires

2015-06-19Sean P. NolanChief Executive OfficerArticle
2016-07-12Michael B. JohannesenSVP General Counsel & Chief Compliance OfficerArticle
2017-02-16Rick ModiSVP/Chief Business OfficerArticle

AveXis New Location/Offices

2019-02-20Durham, NCArticle

AveXis Hiring Plans

DateNumber of EmployeesLocationReference
2019-02-20200North CarolinaArticle